Company intelligence / Profile preview
Jyong Biotech Ltd.
- Ownership
- Private
- Employees
- ~31
- Development stage
- Phase 3
Overview
Jyong Biotech is a Taiwan-based biotech company focused on developing plant-derived drugs for urinary system diseases. Its lead candidate, MCS-2, is in Phase III trials for BPH/LUTS with an NDA resubmission planned after addressing FDA comments. Other pipeline assets include PCP (Phase II, prostate cancer prevention) and IC (preclinical, interstitial cystitis). The company recently raised $20 million via a Nasdaq IPO to fund advanced clinical trials.
- Therapeutic areas
- OncologyNephrologyMen's Health
- Modalities
- Plant-derived drugsNanocarrier-based formulations (micelles)
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Jyong Biotech Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jyong Biotech Ltd..